Zhina Sadeghi, MD
Urogynecology and Reconstructive Pelvic Surgery · Orange, CANPI 1346684867
Payments from drug & device makers
What this record shows
This record is dominated by grants: $10,000 of the $15,189 with a category attached, or 65.8%. Medtronic accounts for 67.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $10,000 and has fallen 97.0% since, to $295 in 2025.
Across 40 payments — averaging $379.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Intuitive Surgical$4K
- Boston Scientific$513
- Calyxo, Inc.$226
- Coloplast$148
- Integra Lifesciences Corporation$144
- plus $181 from 4 others
What the payments were for
- Grants$10,00066%
- Travel & lodging$1,0967%
- Food & beverage$1,59310%
- Education$2,50016%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 6 | $10,284 |
| Intuitive Surgical | 14 | $3,692 |
| Boston Scientific | 10 | $513 |
| Calyxo, Inc. | 3 | $226 |
| Coloplast | 1 | $148 |
| Integra Lifesciences Corporation | 1 | $144 |
| Axonics, Inc. | 2 | $77 |
| Sumitomo Pharma America, Inc. | 1 | $50 |
| Merck | 1 | $31 |
| Dendreon Pharmaceuticals LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$10,141
- DA VINCI SP$1,500
- DAVINCI XI$1,000
- Da Vinci Surgical System$878
- INTEGRA$433
- ALTIS$148
- INTEGRA DERMAL REGENERATION TEMPLATE$144
- PRIMATRIX$144
- CVAC Aspiration System$101
How this compares
$15,189 in reported general payments places this provider in the 85th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 125 | $123,718 |
| GemtesaVibegron | 12 | $7,269 |
| Estradiol | 107 | $6,863 |
| Fosfomycin Tromethamine | 13 | $3,662 |
| Trospium Chloride | 101 | $3,194 |
| Methenamine Hippurate | 30 | $1,703 |
| Tamsulosin Hcl | 83 | $1,108 |
| Tolterodine Tartrate ErTolterodine Tartrate | 17 | $931 |
| Cefdinir | 19 | $321 |
| Tobramycin Sulfate | 17 | $301 |
| Solifenacin Succinate | 13 | $276 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 90 | $252 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $160 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 28 | $150 |
| Levofloxacin | 46 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $50 | $7,26912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Orange
- Jennifer GruenenfelderOrange$76K
- Felicia LaneOrange$29K
- Olivia ChangOrange$5K
- Kristen BuonoOrange$5K
- Andrew BrillSan Francisco$345K
- Bilal KaakiRiverside$301K
- Savitha KrishnanMountain View$243K
- Peter CastilloLos Gatos$95K
- Bruce Kahnla Jolla$79K
- Traci ItoSan Francisco$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.